Verrica Pharmaceuticals Inc (VRCA)
1.00
+0.01
(+1.01%)
USD |
NASDAQ |
Nov 22, 16:00
1.00
0.00 (0.00%)
After-Hours: 20:00
Verrica Pharmaceuticals Enterprise Value: 65.49M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 65.49M |
| November 20, 2024 | 60.81M |
| November 19, 2024 | 60.93M |
| November 18, 2024 | 60.85M |
| November 15, 2024 | 58.35M |
| November 14, 2024 | 59.71M |
| November 13, 2024 | 58.90M |
| November 12, 2024 | 62.30M |
| November 11, 2024 | 64.21M |
| November 08, 2024 | 58.19M |
| November 07, 2024 | 52.46M |
| November 06, 2024 | 54.38M |
| November 05, 2024 | 56.71M |
| November 04, 2024 | 85.56M |
| November 01, 2024 | 90.12M |
| October 31, 2024 | 84.19M |
| October 30, 2024 | 93.31M |
| October 29, 2024 | 96.96M |
| October 28, 2024 | 91.48M |
| October 25, 2024 | 89.20M |
| October 24, 2024 | 88.75M |
| October 23, 2024 | 89.20M |
| October 22, 2024 | 92.85M |
| October 21, 2024 | 91.94M |
| October 18, 2024 | 93.31M |
| Date | Value |
|---|---|
| October 17, 2024 | 86.92M |
| October 16, 2024 | 89.20M |
| October 15, 2024 | 83.73M |
| October 14, 2024 | 85.10M |
| October 11, 2024 | 81.45M |
| October 10, 2024 | 79.17M |
| October 09, 2024 | 78.72M |
| October 08, 2024 | 78.72M |
| October 07, 2024 | 81.45M |
| October 04, 2024 | 80.08M |
| October 03, 2024 | 86.47M |
| October 02, 2024 | 70.96M |
| October 01, 2024 | 82.82M |
| September 30, 2024 | 86.47M |
| September 27, 2024 | 82.93M |
| September 26, 2024 | 82.50M |
| September 25, 2024 | 81.65M |
| September 24, 2024 | 85.92M |
| September 23, 2024 | 85.49M |
| September 20, 2024 | 88.05M |
| September 19, 2024 | 93.60M |
| September 18, 2024 | 89.76M |
| September 17, 2024 | 86.34M |
| September 16, 2024 | 91.46M |
| September 13, 2024 | 94.88M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
46.43M
Minimum
Nov 09 2022
414.05M
Maximum
Mar 15 2021
211.24M
Average
207.28M
Median
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 11.76B |
| Elite Pharmaceuticals Inc | 657.76M |
| Eagle Pharmaceuticals Inc | -- |
| TELA Bio Inc | 137.50M |
| Terns Pharmaceuticals Inc | 112.22M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.86M |
| Revenue (Quarterly) | -1.781M |
| Total Expenses (Quarterly) | 18.92M |
| EPS Diluted (Quarterly) | -0.49 |
| Earnings Yield | -184.0% |
| Normalized Earnings Yield | -184.00 |